The case for inpatient initiation of antiarrhythmic therapy

Journal of Cardiovascular Electrophysiology

Volumn 10, Issue 3, 1999, Pages 482-487

  Myerburg, Robert J ^a   Kloosterman, Martin ^a   Yamamura, Kenneth ^a   Mitrani, Raul ^a   Interian Jr , Alberto ^a   Castellanos, Agustin ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; SOTALOL;

ANTIARRHYTHMIC ACTIVITY; ARTICLE; BRADYCARDIA; CLINICAL FEATURE; DISEASE CLASSIFICATION; DRUG CLASSIFICATION; HEART ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HOSPITAL PATIENT; HUMAN; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MEDICOLEGAL ASPECT; OUTPATIENT; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0033039519     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1999.tb00702.x     Document Type: Article

References (23)

1. Prystowsky EN, Benson DW, Fuster V, et al: Management of patients with atrial fibrillation: A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation 1996;93:1262-1277.
2. Prystowsky EN: Proarrhythmia during drug treatment of supraventricular tachycardia: Paradoxical risk of sinus rhythm for sudden death. Am J Cardiol 1996;78: 35-41.
3. Simons GR, Eisenstein EL, Shaw LJ, et al: Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias. Am J Cardiol 1997; 80:1551-1557.
4. Maisel WH, Kuntz KM, Reimold SC, et al: Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med 1997;127:281-284.
5. Chung MK, Schweikert RA, Wilkoff BL, et al: Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol 1998;32:169-176.
6. Selzer A, Wray HW: Quinidine syncope: Paroxysmal ventricular fibrillation occuring during treatment of chronic atrial arrhythmias. Circulation 1964;30:17-26.
7. Myerburg RJ, Kessler KM, Chakko S, et al: Future evaluation of antiarrhythmic therapy. Am Heart J 1994; 127:1111-1118.
8. Juul-Möller S, Edvardsson N, Rehnqvist-Ahlberg N: Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990;82:1932-1939.
9. Antman EM, Beamer AD, Cantillon C, et al: Therapy of refractory symptomatic atrial fibrillation and atrial flutter: A staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990;15:698-670.
10. Velebit V, Podrid P, Lown B, et al: Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 1982;65:886-894.
11. Rinkenberger RL, Prystowsky EN, Jackman WM, et al: Drug conversion of nonsustained ventricular tachycardia to sustained ventricular tachycardia during serial electrophysiologic studies: Identification of drugs that exacerbate tachycardia and potential mechanisms. Am Heart J 1982;103:177-184.
12. Poser RF, Podrid PJ, Lombardi F, et al: Aggravation of arrhythmia induced with antiarrhythmic drugs during electrophysiologic testing. Am Heart J 1995;110:9-16.
13. Falk RH: Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989;111:107-111.
14. Myerburg RJ, Kessler KM, Cox MM, et al: Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol. Circulation 1989;80: 1571-1579.
15. The Cardiac Arrhythmias Suppression Trial (CAST) Investigators: Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1991;321:406-412.
16. Echt DS, Liebson PR, Mitchell B, et al, and the CAST Investigators: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324: 781-788.
17. Akhtar M, Breithardt G, Camm AJ, et al: CAST and beyond: Implications of the Cardiac Arrhythmia Suppression Trial. Circulation 1990;81:1123-1127.
18. Woosley RL, Chen Y, Freiman JP, et al: Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269: 1532-1536.
19. Falk RH: Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 1992;117:141-150.
20. Minardo JD, Heger JJ, Miles WM, et al: Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. N Engl J Med 1988;319: 257-262.
21. Capucci A, Boriani G, Botto GL, et al: Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol 1994; 74:503-505.
22. Ellenbogen KA, Stambler BS, Wood MA, et al: Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response study. J Am Coll Cardiol 1996;28:130-136.
23. Physicians' Desk Reference. Medical Economics Company, Montvale, NJ, 1998.